Combined therapy with thrombospondin-1 type I repeats (3TSR) and chemotherapy induces regression and significantly improves survival in a preclinical model of advanced stage epithelial ovarian cancer.
about
Original insights on thrombospondin-1-related antireceptor strategies in cancer.Thrombospondin-1-Based Antiangiogenic Therapy.Matricellular proteins in drug delivery: Therapeutic targets, active agents, and therapeutic localizationTumor-associated macrophages drive spheroid formation during early transcoelomic metastasis of ovarian cancer.Tumor vessel normalization after aerobic exercise enhances chemotherapeutic efficacy.Akt isoform specific effects in ovarian cancer progression.The Pleiotropic Role of L1CAM in Tumor VasculatureProperdistatin inhibits angiogenesis and improves vascular function in human melanoma xenografts with low thrombospondin-1 expression.Development of a prosaposin-derived therapeutic cyclic peptide that targets ovarian cancer via the tumor microenvironment.Puzzling and ambivalent roles of malarial infections in cancer development and progression.The Role of Angiogenesis in the Persistence of Chemoresistance in Epithelial Ovarian Cancer.ASK1-dependent endothelial cell activation is critical in ovarian cancer growth and metastasis.Distinct C-mannosylation of netrin receptor thrombospondin type 1 repeats by mammalian DPY19L1 and DPY19L3.Thrombospondin1 (TSP1) replacement prevents cerebral cavernous malformations.Integration of pro- and anti-angiogenic signals by endothelial cells.Low-dose metronomic delivery of cyclophosphamide is less detrimental to granulosa cell viability, ovarian function, and fertility than maximum tolerated dose delivery in the mouse.Thrombospondin-I concentrations behavior in plasma of patients with ovarian cancer.Human expression patterns: qualitative and quantitative analysis of thrombospondin-1 under physiological and pathological conditions.Expression of thrombospondin-1 by tumor cells in patient-derived ovarian carcinoma xenografts.
P2860
Q36221374-512ECA1C-2D04-4B60-8202-48D718075408Q36417463-18AF9A90-BB47-4EAF-A0E0-1F7991E6E58FQ36578825-A5E683C0-818F-4F79-B840-C36102DF5B90Q37395811-E85ADAF5-C229-4ED5-9AC4-24392196A053Q37662252-CFC28264-2435-4F9E-AC92-901331D1394DQ37688855-BB392B9F-4DDB-4FE5-81B7-F0E1F15221C5Q37690651-942319DF-9BD6-4DB8-9E37-19D09AA5A862Q37718288-92003C6C-D56D-4FEE-B885-6BEC09786820Q38787442-2048DF73-E401-414B-9F0F-A05B349583D0Q38822157-A675B5D8-F29B-4D08-9563-6C7FA58DEDB3Q39815570-18E068E0-1A22-4753-98F9-A66AD4368D9CQ42269997-E5E6F319-B025-4B5B-B883-A02C5492D997Q42316832-58461F55-DFF6-4218-80B9-6BC0C1BE5636Q46147842-F705690B-FD83-46E3-853C-5B03ADEC6519Q47267571-4DF8712D-48C5-4622-8787-4F24134A8EB9Q47612055-130A27A7-4B1A-4ECA-B227-3A292639D391Q47717341-46708B08-65BF-4AF6-960F-69D6BC20483DQ50019794-31893374-D2F2-46DA-8549-CBAF0ED4B405Q53518575-79E5A925-8F36-4B74-9836-C121D87F3B37
P2860
Combined therapy with thrombospondin-1 type I repeats (3TSR) and chemotherapy induces regression and significantly improves survival in a preclinical model of advanced stage epithelial ovarian cancer.
description
2014 nî lūn-bûn
@nan
2014 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Combined therapy with thrombos ...... age epithelial ovarian cancer.
@ast
Combined therapy with thrombos ...... age epithelial ovarian cancer.
@en
type
label
Combined therapy with thrombos ...... age epithelial ovarian cancer.
@ast
Combined therapy with thrombos ...... age epithelial ovarian cancer.
@en
prefLabel
Combined therapy with thrombos ...... age epithelial ovarian cancer.
@ast
Combined therapy with thrombos ...... age epithelial ovarian cancer.
@en
P2093
P2860
P356
P1433
P1476
Combined therapy with thrombos ...... tage epithelial ovarian cancer
@en
P2093
Jack Lawler
Jim Petrik
Mark Duquette
P2860
P304
P356
10.1096/FJ.14-261636
P407
P577
2014-11-13T00:00:00Z